Loading…
Loading…
CPAAU (Conyers Park III Acquisition Corp.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
CPAAU does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for CPAAU and 80,000+ other tickers.
See exactly how CPAAU's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CPAAU and 80,000+ other tickers.
Conyers Park III Acquisition Corp. is not currently engaged in any substantive business operations. Its core objective is to complete a strategic business combination, which could take the form of a merger, capital stock exchange, asset acquisition, stock purchase, corporate reorganization, or a comparable arrangement, involving one or more entities. The company specifically aims to identify opportunities within the consumer sector and related businesses. This firm was established in 2021 and is headquartered in Naples, Florida.
The summer IPO market is wrapping up, and while we could see a few more launches, this past week's two deals should be some of the last IPOs before fall. SPAC activity continued to bounce back, with 17 blank check IPOs during the week.
NAPLES, Fla., Aug. 12, 2021 /PRNewswire/ -- Conyers Park III Acquisition Corp. (NASDAQ: CPAAU) (the "Company"), a special purpose acquisition company formed for the purpose of entering into a combination with one or more businesses, today announced the closing of its initial public offering of 35,000,000 units at a price of $10.00 per share.
After a record breaking number of deals last week, the IPO market cooled off for the shortened holiday week, with just two micro-cap IPOs raising $45 million. Preclinical RNA biotech Transcode Therapeutics priced at $4 to raise $25 million at a $54 million market cap.
This week's Alpha Trader podcast features hosts Aaron Task and Stephen Alpher speaking with Lyn Alden Schwartzer and Chris DeMuth.
Conyers Park II is one of the best available SPACs. Their warrants offer leverage on a successful deal.